Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2013

01-12-2013 | Original Article

Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET/CT imaging: BAY 85-8050

Authors: Kamilla Smolarz, Bernd Joachim Krause, Frank Philipp Graner, Franziska Martina Wagner, Hans-Jürgen Wester, Tina Sell, Claudia Bacher-Stier, Lüder Fels, Ludger Dinkelborg, Markus Schwaiger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2013

Login to get access

Abstract

Purpose

Novel tracers for the diagnosis of malignant disease with PET and PET/CT are being developed as the most commonly used 18F deoxyglucose (FDG) tracer shows certain limitations. Employing radioactively labelled glutamate derivatives for specific imaging of the truncated citrate cycle potentially allows more specific tumour imaging. Radiation dosimetry of the novel tracer BAY 85-8050, a glutamate derivative, was calculated and the effective dose (ED) was compared with that of FDG.

Methods

Five healthy volunteers were included in the study. Attenuation-corrected whole-body PET/CT scans were performed from 0 to 90 min, at 120 and at 240 min after injection of 305.0 ± 17.6 MBq of BAY 85-8050. Organs with moderate to high uptake at any of the imaging time points were used as source organs. Total activity in each organ at each time point was measured. Time–activity curves (TAC) were determined for the whole body and all source organs. The resulting TACs were fitted to exponential equations and accumulated activities were determined. OLINDA/EXM software was used to calculate individual organ doses and the whole-body ED from the acquired data.

Results

Uptake of the tracer was highest in the kidneys due to renal excretion of the tracer, followed by the pancreas, heart wall and osteogenic cells. The mean organ doses were: kidneys 38.4 ± 11.2 μSv/MBq, pancreas 23.2 ± 3.8 μSv/MBq, heart wall 17.4 ± 4.1 μSv/MBq, and osteogenic cells 13.6 ± 3.5 μSv/MBq. The calculated ED was 8.9 ± 1.5 μSv/MBq.

Conclusion

Based on the distribution and dose estimates, the calculated radiation dose of BAY 85-8050 is 2.67 ± 0.45 mSv at a patient dose of 300 MBq, which compares favourably with the radiation dose of FDG (5.7 mSv).
Literature
1.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.PubMedCrossRef
2.
Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48:78S–88S.PubMed
3.
Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–9.PubMed
4.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77.PubMedCrossRef
5.
6.
Krasikova RN, Kuznetsova OF, Fedorova OS, Belokon YN, Maleev VI, Mu L, et al. 4-[(18)F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem. 2011;54:406–10.PubMedCrossRef
7.
8.
Koglin N, Friebe M, Berndt M, Graham K, Krasikova R, Kuznetsova O, et al. [F-18]BAY 85-8050: a novel tumor specific probe for PET imaging – preclinical results. J Nucl Med. 2010;51 Suppl 2:1535.
9.
Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med. 2008;49:853–60.PubMedCrossRef
10.
Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine; 1991.
11.
Jakoby B, Long M, Carr C, Townsend D. Physical performance of a new combined PET/CT scanner. J Nucl Med. 2007;48 Suppl 2:46P.
12.
Janssen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. J Appl Physiol. 2000;89:81–8.PubMed
13.
Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102–6.PubMed
14.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed
15.
International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon; 1998. ICRP Publication 80: Addendum 2 to Publication 53.
16.
Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–8.PubMed
17.
Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller HW, et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30:519–24.PubMedCrossRef
Metadata
Title
Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET/CT imaging: BAY 85-8050
Authors
Kamilla Smolarz
Bernd Joachim Krause
Frank Philipp Graner
Franziska Martina Wagner
Hans-Jürgen Wester
Tina Sell
Claudia Bacher-Stier
Lüder Fels
Ludger Dinkelborg
Markus Schwaiger
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2502-z

Other articles of this Issue 12/2013

European Journal of Nuclear Medicine and Molecular Imaging 12/2013 Go to the issue

Original Article

Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate

Image of the Month

Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG

Original Article

Reduced cardiac 123I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: a comparative study with Parkinson’s disease

Original Article

Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion

Editorial Commentary

Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Letter to the Editor

Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity: further comments